Cargando…

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease

BACKGROUND: Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still's disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case serie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitale, Antonio, Berlengiero, Virginia, Sota, Jurgen, Ciarcia, Luisa, Ricco, Nicola, Barneschi, Sara, Mourabi, Mariam, Lopalco, Giuseppe, Marzo, Chiara, Bellisai, Francesca, Iannone, Florenzo, Frediani, Bruno, Cantarini, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584965/ https://www.ncbi.nlm.nih.gov/pubmed/33122969 http://dx.doi.org/10.1155/2020/8054961

Ejemplares similares

Clinical profile and evolution of patients with juvenile-onset Behçet’s syndrome over a 25-year period: insights from the AIDA network
por: Sota, Jurgen, et al.
Publicado: (2021)

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry
por: Vitale, Antonio, et al.
Publicado: (2022)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network
por: Gaggiano, Carla, et al.
Publicado: (2021)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Off-label use of canakinumab in pediatric rheumatology and rare diseases
por: Del Giudice, Emanuela, et al.
Publicado: (2022)

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2017)

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network
por: Gaggiano, Carla, et al.
Publicado: (2020)

Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2015)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives
por: Rotondo, Cinzia, et al.
Publicado: (2015)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Update on the Medical Management of Gastrointestinal Behçet's Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2017)

Canakinumab and mycophenolate mofetil in managing proteinuria/renal amyloidosis secondary to adult-onset Still’s disease
por: Feng, Jin, et al.
Publicado: (2023)

Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives
por: Lopalco, Giuseppe, et al.
Publicado: (2015)

Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease
por: Cattalini, Marco, et al.
Publicado: (2015)

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network
por: Vitale, Antonio, et al.
Publicado: (2021)

Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
por: Vitale, Antonio, et al.
Publicado: (2020)

Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
por: Vitale, Antonio, et al.
Publicado: (2019)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
por: Conticini, Edoardo, et al.
Publicado: (2020)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies
por: Ruscitti, Piero, et al.
Publicado: (2020)

Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases
por: Gaggiano, Carla, et al.
Publicado: (2019)

New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy
por: Fabiani, Claudia, et al.
Publicado: (2020)

Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa
por: Annicchiarico, Giuseppina, et al.
Publicado: (2015)

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study
por: Conticini, Edoardo, et al.
Publicado: (2022)

Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings
por: Hur, Peter, et al.
Publicado: (2021)

The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile
por: Ruscitti, Piero, et al.
Publicado: (2021)

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study
por: Venerito, Vincenzo, et al.
Publicado: (2023)

Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study
por: Floris, Alberto, et al.
Publicado: (2022)

Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases
por: Bettiol, Alessandra, et al.
Publicado: (2019)

Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease
por: Lucherini, OM, et al.
Publicado: (2015)

Effects of antiresorptive agents on body composition: a case-control retrospective study
por: Al Khayyat, Suhel Gabriele, et al.
Publicado: (2023)

Peripheral Macrovascular Involvement in Systemic Sclerosis: A Cohort Study by Color and Spectral Doppler Ultrasonography
por: D’Alessandro, Roberto, et al.
Publicado: (2023)

Untangling the Web of Systemic Autoinflammatory Diseases
por: Rigante, Donato, et al.
Publicado: (2014)

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease
por: Shaul, Eliana, et al.
Publicado: (2022)

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_59l4o6b6n0lp26mlc7frrm59c4